Trump administration too distracted to conduct an effective vetting process.
Reported in Dr. Brenda Fitzgerald, C.D.C. Director, Resigns Over Tobacco and Other Investments. (The New York Times, 1/31/2018)
Related reading:
Will Azar Practice 'Art Of The Deal' Capitalism At Trump's HHS? (Forbes, 1/29/2018)
That was then, this is now. But challenged over the doubling of the price of insulin and several other important Eli Lilly & Co. drugs during his tenure there, Azar did say he’d pursue leverage down other paths. At Lilly, he suggested, his job was profit maximization, but as HHS chief his task would be getting the best deal for the public. The key was creating the right incentives.
No comments:
Post a Comment